All Alzheimer's articles
-
OpinionRegulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
-
Business
Second Alzheimer’s antibody approved in the US
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
-
Business
Alzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
-
Opinion
Alzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
Opinion
When regulatory cooperation goes too far, we all lose
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?
-
Business
Alzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients
-
Research
Biochemical mystery unfolds as elemental metals found in Alzheimer’s patients’ brains
In a discovery that raises more question than it answers, researchers have found zero-oxidation-state iron and copper deposits inside amyloid plaques
-
Business
Regulatory panel unconvinced by Alzheimer’s antibody evidence
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
-
News
Swipe right to help in the fight against Huntington’s disease
Citizen science project improves understanding of protein misfolding disorders like Huntington’s and Alzheimer’s diseases
-
-
Research
Alzheimer’s therapy has click chemistry use, then remove, brain copper build-ups
In situ drug synthesis catalysed by endogenous copper
-
Business
Sixth in a line of Alzheimer’s drugs fails in trials
Treatments designed to stop amyloid peptide formation all seem to cause cognitive impairment rather than prevent it
-
Podcast
Amantadine
Katrina Krämer investigates how one of the smallest small molecule drugs around saved Jeanna Giese's life
-
Research
Alzheimer’s linked to infection of the brain by gum disease bacterium
Drug firm is developing treatment to inhibit bacterial enzymes believed to be damaging important protein
-
Research
Scorpion venom peptide engineered to sting brain disorders
Structure used to escort nanoparticles across blood–brain barrier also resists protease degradation
-
Feature
Understanding Alzheimer’s
After hundreds of failed drug candidates, James Mitchell Crow asks if this is the last roll of the dice for the amyloid theory of Alzheimer’s disease
-
News
Beetroot beats route to Alzheimer's
Betanin, the compound that gives beetroot it’s distinctive purple colour, may slow the process of protein misfolding that is linked to Alzheimer’s disease
-
Business
Dementia slips down pharma agenda
Pfizer, Shire, Acorda and Axovant rethink their neuroscience strategies
-
Research
Route to fiendishly complex marine molecule cut in half
Shortcut to promising natural product already in Alzheimer’s and HIV trials
-
News
Alzheimer’s disease: have drug developers been on the wrong track?
Dementia drug developers urged to look beyond amyloid
